Steps to enroll
Enroll for immediate access to NOURIANZ™ (istradefylline) with a free 28-day supply
Download and print the Kyowa Kirin Cares enrollment form, fill it out with your patient's information, and fax it to 833-447-4399.
While a case manager begins the benefits investigation (BI), Kyowa Kirin Cares will provide eligible patients with immediate access to NOURIANZ through the Quick Start program, which gives a newly prescribed patient a free 28-day supply of NOURIANZ.
After the BI is complete, a Kyowa Kirin Cares case manager will help your patient navigate their reimbursement and access options based on their insurance coverage.
Kyowa Kirin Cares will coordinate to get your patient their regular prescription of NOURIANZ through a designated specialty pharmacy. Eligible patients may pay no more than $20 per month for their prescription through the co-pay card program.
Access and assistance
Assistance with access and reimbursement
A Kyowa Kirin Cares case manager can help your patients understand their access options regardless of their insurance coverage or status.
Kyowa Kirin offers co-pay assistance for eligible commercially insured patients. Review the co-pay assistance terms and conditions to determine if your patients with commercial insurance qualify.a,b
In most cases, Kyowa Kirin doesn’t offer a program for government- or military-insured patients.c A case manager may be able to refer them to independent charitable foundations and/or inform them about federal plan selections.
Kyowa Kirin offers a patient assistance program for eligible uninsured patients. Download the application to review the terms and conditions and determine if your patients without insurance may qualify.c
aPatients must be US residents with an active primary commercial plan; patients with federal or state government insurance such as Medicare, Medicaid, and Tricare are not eligible for co-pay assistance. Other terms and conditions may apply.
bCommercially insured patients do not need to participate in Kyowa Kirin Cares to be eligible for co-pay assistance.
cPatients must be US residents with no active medical or pharmacy benefit insurance and an annual gross income ≤400% of the federal poverty level, confirmed by electronic income verification response or documented proof of income.
Connect your patients to support
Kyowa Kirin Cares helps provide your patients with personal support throughout their journey with NOURIANZ. By enrolling in Kyowa Kirin Cares, you’re providing a resource to your patients, which may be particularly helpful for patients with medication affordability concerns. However, even if you choose not to enroll in Kyowa Kirin Cares, your patients can still enroll on their own to receive ongoing support from a case manager while taking NOURIANZ.
A dedicated case manager will be available to
Answering general questions about NOURIANZ
Provide external resources when applicable
Help patients manage barriers to adherence
Help patients navigate their financial options
The information provided by the case manager to your patients is for informational purposes only and does not constitute medical advice. It is not intended to replace a discussion between you and your patient. All decisions regarding patient care must be made by a patient’s healthcare provider considering the unique characteristics of each patient.
Important forms and resources
Access Kyowa Kirin forms as well as useful NOURIANZ information and resources.
Download the Kyowa Kirin Cares enrollment form to get started with the program.
NOURIANZ patient brochure
Download the patient brochure to help guide your patients through NOURIANZ treatment.
Letter of medical necessity
Download this template letter of medical necessity for appropriate patient cases.
This Kyowa Kirin Cares brochure provides a quick reference for program offerings.
Patient assistance program
Download the patient assistance program application for your uninsured patients.
NOURIANZ™ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
Important Safety Information
Warnings and Precautions:
Dyskinesia: NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo.
Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ.
Impulse Control / Compulsive Behaviors: Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson’s disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40 mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20 mg or placebo.
The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers.
Pregnancy: Based on animal data, may cause fetal harm.
Hepatic impairment: The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment is 20 mg once daily. Avoid use in patients with severe hepatic impairment.
The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20 mg, 40 mg, and placebo, respectively.
Please see full Prescribing Information.